# Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

> **NCT03409679** · PHASE3 · TERMINATED · sponsor: **Polyphor Ltd.** · enrollment: 41 (actual)

## Conditions studied

- Pneumonia

## Interventions

- **DRUG:** Murepavadin
- **DRUG:** Two anti-pseudomonal antibiotics

## Key facts

- **NCT ID:** NCT03409679
- **Lead sponsor:** Polyphor Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-23
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-17
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Safety data review
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03409679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03409679, "Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03409679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*